Current and Emerging Clinical Applications of PSMA PET Diagnostic Imaging for Prostate Cancer
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Prostate-specific membrane antigen (PSMA) is highly expressed on most prostate cancer (PCa) cells, and several PSMA ligands for PET imaging are now available worldwide. 68Ga-PSMA-11 has already received U.S. Food and Drug Administration and European Medicines Agency approval, and use of PSMA PET is currently suggested by several international guidelines for investigating PCa in different clinical settings. In primary PCa, PSMA PET has been shown to be superior to cross-sectional imaging for the detection of pelvic lymph nodes and distant metastases with subsequent clinical management changes. Additionally, it might also have a role in intraprostatic tumor localization, especially when combined with multiparametric MRI. In a setting of PCa recurrence, higher detection rates have been observed than for any other available imaging techniques, especially at low prostate-specific antigen values. Furthermore, PSMA PET consistently led to a shift in clinical management, thus increasing the proportion of radiotherapy, surgery, or other focal therapies at the expense of systemic options or no treatment. In oligometastatic disease after radical surgery, PSMA PET may be relevant in guiding a metastasis-directed therapy approach, as preliminary data seem to suggest a benefit in terms of progression-free survival after treatment of PSMA PET–positive lesions. As a staging and gatekeeping technique, PSMA PET represents a reliable whole-body imaging procedure in combination with second-line therapy of castration-resistant PCa, as well as being pivotal when assessing patients eligible for radioligand therapy such as 177Lu-PSMA. This critical review aims at providing a comprehensive overview of the latest literature on the current or emerging main indications, as well as a general outlook on the recommended interpretation criteria for PSMA PET imaging.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · cited 1×
“PSMA-PET parameters, as well as the RECIST 1.1 54 , were significantly associated with PSA response.”
MethodInfluentialSiegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160 · cited 1×
“Prostate cancer (PCa) is the most common malignancy in men, and is associated with high morbidity and mortality rates 1 .”
BackgroundMottet, N., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Cumberbatch, M. G., De Santis, M., Fanti, S., Fossati, N., Gandaglia, G., Gillessen, S., et al. (2021) · European Urology · doi:10.1016/j.eururo.2020.09.042 · Cited by 2,802 · cited 2×
“Biopsy Guidance mpMRI should be performed on all subjects presenting with clinically suspected PCa before any biopsy attempt in order to guide the biopsy to significant foci in accordance with the most recent recommendations (17).”
BackgroundMethodSelf-citationHofman, M. S., Lawrentschuk, N., Francis, R. J., Tang, C., Vela, I., Thomas, P., Rutherford, N., Martin, J. M., Frydenberg, M., Shakher, R., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30314-7 · Cited by 2,040 · cited 1×
“The recently published results of the proPSMA study are a game changer in staging high-risk PCa patients (25).”
ResultPalma, D. A., Olson, R., Harrow, S., Gaede, S., Louie, A. V., Haasbeek, C., Mulroy, L., Lock, M., Rodrigues, G. B., Yaremko, B. P., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32487-5 · Cited by 1,857 · cited 1×
“The oligometastatic state is proposed as intermediate stage of cancer spread between localized and systemic disease, enabling potential opportunity for metastasis-directed therapies (MDT) to delay the emergence of polymetastatic disease 43 .”
BackgroundScher, H. I., Morris, M. J., Stadler, W. M., Higano, C., Basch, E., Fizazi, K., Antonarakis, E. S., Beer, T. M., Carducci, M. A., Chi, K. N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.2702 · Cited by 1,654 · cited 1×
“In this regard, the PSMA PET Progression Criteria were proposed to define disease progression (56), since the criteria of the Prostate Cancer Clinical Trials Working Group include only laboratory parameters and conventional imaging but no molecular imaging (57).”
BackgroundOst, P., Reynders, D., Decaestecker, K., Fonteyne, V., Lumen, N., De Bruycker, A., Lambert, B., Delrue, L., Bultijnck, R., Claeys, T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.4853 · Cited by 1,351
Parker, C. C., James, N. D., Brawley, C. D., Clarke, N. W., Hoyle, A. P., Ali, A., Ritchie, A. W. S., Attard, G., Chowdhury, S., Cross, W., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32486-3 · Cited by 1,262 · cited 1×
“Disease volume and distribution have prognostic implications for patients’ management, quality of life and survival, and thus prompt recognition of oligometastatic PCa is desirable 44 .”
BackgroundHofman, M. S., Violet, J., Hicks, R. J., Ferdinandus, J., Thang, S. P., Akhurst, T., Iravani, A., Kong, G., Ravi Kumar, A., Murphy, D. G., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30198-0 · Cited by 1,174 · cited 1×
“Experience derived from (177)Lu-PSMA suggests a dual-tracer approach using both PSMA and (18)F-FDG for patient selection before treatment (51,52).”
MethodPhillips, R., Shi, W. Y., Deek, M., Radwan, N., Lim, S. J., Antonarakis, E. S., Rowe, S. P., Ross, A. E., Gorin, M. A., Deville, C., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.0147 · Cited by 1,159 · cited 1×
“Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer) study is the first clinical trial on PSMA PET–directed salvage therapy (47).”
BackgroundCornford, P., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Cumberbatch, M. G., De Santis, M., Fanti, S., Fossati, N., Gandaglia, G., Gillessen, S., et al. (2021) · European Urology · doi:10.1016/j.eururo.2020.09.046 · Cited by 1,079 · cited 3×
“Clinical stage EAU-EANM-ESTRO-ESURSIOG (17,35) Strength rating ASCO (40) Strength rating”
BackgroundMethodSelf-citationPerera, M., Papa, N., Roberts, M., Williams, M., Udovicich, C., Vela, I., Christidis, D., Bolton, D., Hofman, M. S., Lawrentschuk, N., et al. (2020) · European Urology · doi:10.1016/j.eururo.2019.01.049 · Cited by 958 · cited 3×
“The emerging data suggest that novel prostate-specific membrane antigen (PSMA)–based radioligands carry the highest diagnostic value in the imaging of PCa (7).”
BackgroundAfshar-Oromieh, A., Malcher, A., Eder, M., Eisenhut, M., Linhart, H. G., Hadaschik, B. A., Holland-Letz, T., Giesel, F. L., Kratochwil, C., Haufe, S., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2298-2 · Cited by 915 · cited 1×
“PSMA-11 (PSMA-HBEDCC) (12) (68)Ga Imaging Most widely used in literature; European Medicines Agency and Food and Drug Administration approval (68)Ga-related disadvantages; high accumulation in urinary tract”
BackgroundTumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer
Ghosh, A., & Heston, W. D. W. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10661 · Cited by 878 · cited 1×
“…PSMA-ligands have been synthetized, based on both small urea-based molecules and antibodies, bound with Gallium-68 rather than Fluorine-18 or other isotopes, using both positron or single-photon emission tomography 10–16 while more radio-labelled PSMA ligands are expected in the future (Table 1).”
BackgroundFendler, W. P., Calais, J., Eiber, M., Flavell, R. R., Mishoe, A., Feng, F. Y., Nguyen, H. G., Reiter, R. E., Rettig, M. B., Okamoto, S., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0096 · Cited by 779 · cited 2×
“In this regard the PSMA PET Progression Criteria (PPP) were proposed to define disease progression 55 , since the criteria of the Prostate Cancer Clinical Trials Working Group (PCWG3) include only laboratory parameters and CI but no molecular imaging 56 .”
BackgroundUpregulation of prostate-specific membrane antigen after androgen-deprivation therapy
Wright, G. L., Mayer Grob, B., Haley, C., Grossman, K., Newhall, K., Petrylak, D., Troyer, J., Konchuba, A., Schellhammer, P. F., & Moriarty, R. (1996) · Urology · doi:10.1016/s0090-4295(96)00184-7 · Cited by 635 · cited 1×
“In vitro studies evaluating the effect of ADT on PSMA expression were firstly published by Wright 57 .”
BackgroundEiber, M., Herrmann, K., Calais, J., Hadaschik, B., Giesel, F. L., Hartenbach, M., Hope, T., Reiter, R., Maurer, T., Weber, W. A., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.198119 · Cited by 626 · cited 4×
“PROMISE Criteria The PROMISE criteria are a suggested standardization for PSMA PET both for reading based on the intensity of PSMA expression (known as miPSMA scores) and for interpretating the images and staging the disease (known as miTNM scores) (65).”
BackgroundMethodInfluentialGiesel, F. L., Hadaschik, B., Cardinale, J., Radtke, J., Vinsensia, M., Lehnert, W., Kesch, C., Tolstov, Y., Singer, S., Grabe, N., et al. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3573-4 · Cited by 592 · cited 2×
“PSMA-1007 (15) (18)F Imaging Low accumulation in urinary tract High hepatic uptake; higher number of PSMA-positive lesions attributed to benign origin*”
BackgroundMorigi, J. J., Stricker, P. D., van Leeuwen, P. J., Tang, R., Ho, B., Nguyen, Q., Hruby, G., Fogarty, G., Jagavkar, R., Kneebone, A., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.160382 · Cited by 571 · cited 1×
“PSMA-PET demonstrated higher sensitivity than 11C- choline-and/or 18F-fluciclovine-PET in this setting 29,30 and scan positivity increases with higher PSA values 7 .”
BackgroundSelf-citationCalais, J., Ceci, F., Eiber, M., Hope, T. A., Hofman, M. S., Rischpler, C., Bach-Gansmo, T., Nanni, C., Savir-Baruch, B., Elashoff, D., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30415-2 · Cited by 476 · cited 1×
“PSMA PET demonstrated higher sensitivity than (11)C-choline or (18)F-fluciclovine PET in this setting (29,30), and scan positivity increases with higher PSA values (7).”
BackgroundProstate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer
Paschalis, A., Sheehan, B., Riisnaes, R., Rodrigues, D. N., Gurel, B., Bertan, C., Ferreira, A., Lambros, M. B. K., Seed, G., Yuan, W., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.06.030 · Cited by 455 · cited 1×
“However, PSMA has shown a marked inter- and intrapatient heterogeneity (8).”
BackgroundAfshar-Oromieh, A., Hetzheim, H., Kratochwil, C., Benesova, M., Eder, M., Neels, O. C., Eisenhut, M., Kübler, W., Holland-Letz, T., Giesel, F. L., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.161299 · Cited by 427 · cited 1×
“PSMA-617 (13) (68)Ga Imaging and therapy Reduced kidney uptake compared with PSMA-11 (68)Ga-related disadvantages; slightly slower tracer kinetics than for PSMA-11; high accumulation in urinary tract”
BackgroundChen, Y., Pullambhatla, M., Foss, C. A., Byun, Y., Nimmagadda, S., Senthamizhchelvan, S., Sgouros, G., Mease, R. C., & Pomper, M. G. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1357 · Cited by 388 · cited 1×
“DCFPyL (11) (18)F Imaging Low hepatic uptake High accumulation in urinary tract”
BackgroundE-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET
Ceci, F., Oprea-Lager, D. E., Emmett, L., Adam, J. A., Bomanji, J., Czernin, J., Eiber, M., Haberkorn, U., Hofman, M. S., Hope, T. A., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05245-y · Cited by 368 · cited 5×
“TABLE 3 Proposed Reading and Interpretation Criteria by PSMA RADS (66), E-PSMA (67), and PROMISE (65) for PSMA PET”
BackgroundInfluentialSelf-citationHan, S., Woo, S., Kim, Y. J., & Suh, C. H. (2018) · European Urology · doi:10.1016/j.eururo.2018.03.030 · Cited by 331 · cited 1×
“A metaanalysis investigating the impact of PSMA PET on management of BCR patients (11 studies, 908 patients) reported changes in 54% of patients, although substantial heterogeneity among the included studies was noted—that is, differences in clinical settings, types of initial definitive treatment, and baseline charac…”
BackgroundEvans, M. J., Smith-Jones, P. M., Wongvipat, J., Navarro, V., Kim, S., Bander, N. H., Larson, S. M., & Sawyers, C. L. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106383108 · Cited by 316 · cited 1×
“In vivo studies showed that the PSMA expression is increased after ADT while the tumor size is decreased after administration of enzalutamide 58 .”
BackgroundCalais, J., Czernin, J., Cao, M., Kishan, A. U., Hegde, J. V., Shaverdian, N., Sandler, K., Chu, F.-I., King, C. R., Steinberg, M. L., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.201749 · Cited by 279 · cited 1×
“Calais et al. enrolled 270 patients after prostatectomy and before SRT who underwent PSMA-PET at a PSA level < 1 ng/mL (median 0.48 ng/mL) 40 .”
BackgroundInfluentialFendler, W. P., Weber, M., Iravani, A., Hofman, M. S., Calais, J., Czernin, J., Ilhan, H., Saad, F., Small, E. J., Smith, M. R., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1050 · Cited by 266 · cited 12×
“In a retrospective analysis of 80 advanced CRPC patients treated with 223 Ra-dichloride the final outcome was significantly better in the group of patients studied with PSMA-PET before treatment in comparison whit those only staged with CI 49 .”
BackgroundInfluentialEmmett, L., Yin, C., Crumbaker, M., Hruby, G., Kneebone, A., Epstein, R., Nguyen, Q., Hickey, A., Ihsheish, N., O’Neill, G., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.223099 · Cited by 223 · cited 1×
“In this regard, Emmett and colleagues studied with sequential PSMA-PET eight CSPC patients at baseline and after 9, 18 and 28 days from ADT administration (LHRH plus bicalutamide) 60 .”
68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience
Hope, T. A., Truillet, C., Ehman, E. C., Afshar-Oromieh, A., Aggarwal, R., Ryan, C. J., Carroll, P. R., Small, E. J., & Evans, M. J. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.181800 · Cited by 214 · cited 1×
“…PSMA uptake significantly increased in one hormonal naïve patient imaged with PSMA-PET before and after four weeks of ADT (single administration of 7.5-mg leuprolide and 50 mg of bicalutamide/die), in contrast with the significant reduction of PSA levels who dropped down from 66ng/mL to 9ng/mL 59 .”
BackgroundInfluentialOptimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline
Trabulsi, E. J., Rumble, R. B., Jadvar, H., Hope, T., Pomper, M., Turkbey, B., Rosenkrantz, A. B., Verma, S., Margolis, D. J., Froemming, A., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02757 · Cited by 186 · cited 2×
“Clinical stage EAU-EANM-ESTRO-ESURSIOG (17,35) Strength rating ASCO (40) Strength rating”
BackgroundSelf-citationThang, S. P., Violet, J., Sandhu, S., Iravani, A., Akhurst, T., Kong, G., Ravi Kumar, A., Murphy, D. G., Williams, S. G., Hicks, R. J., et al. (2019) · European Urology Oncology · doi:10.1016/j.euo.2018.11.007 · Cited by 183
Rauscher, I., Düwel, C., Haller, B., Rischpler, C., Heck, M. M., Gschwend, J. E., Schwaiger, M., Maurer, T., & Eiber, M. (2018) · European Urology · doi:10.1016/j.eururo.2018.01.006 · Cited by 170
Fanti, S., Hadaschik, B., & Herrmann, K. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.233817 · Cited by 165 · cited 1×
“In this regard the PSMA PET Progression Criteria (PPP) were proposed to define disease progression 55 , since the criteria of the Prostate Cancer Clinical Trials Working Group (PCWG3) include only laboratory parameters and CI but no molecular imaging 56 .”
BackgroundSelf-citationAfshar-Oromieh, A., Debus, N., Uhrig, M., Hope, T. A., Evans, M. J., Holland-Letz, T., Giesel, F. L., Kopka, K., Hadaschik, B., Kratochwil, C., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4079-z · Cited by 162 · cited 1×
“studied the effect of long-term ADT (mean, 7 mo) in 10 CSPC patients (63).”
BackgroundAndriole, G. L., Kostakoğlu, L., Chau, A., Duan, F., Mahmood, U., Mankoff, D. A., Schuster, D. M., Siegel, B. A., Adler, L. P., Belkoff, L. H., et al. (2018) · The Journal of Urology · doi:10.1016/j.juro.2018.08.050 · Cited by 159
Emmett, L., Tang, R., Nandurkar, R., Hruby, G., ROACH, P. J., Watts, J. A., Cusick, T., Kneebone, A. B., Ho, B., Chan, L., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.235028 · Cited by 157 · cited 1×
“A prospective multicenter study (39) was performed to evaluate the predictive value of PSMA PET in 260 men with BCR (PSA of 0.”
MethodSeitz, A. K., Rauscher, I., Haller, B., Kroenke, M., Luther, S., Heck, M. M., Horn, T. D., Gschwend, J. E., Schwaiger, M., Eiber, M. J., et al. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3887-x · Cited by 152 · cited 1×
“In a retrospective study on PSMA PET before and after 3 cycles of docetaxel, 16 metastatic CRPC patients were evaluated (53).”
MethodRowe, S. P., Pienta, K. J., Pomper, M. G., & Gorin, M. A. (2018) · European Urology · doi:10.1016/j.eururo.2017.10.027 · Cited by 150 · cited 8×
“PSMA RADS PSMA RADS is a classification of PSMA PET findings into categories that reflect the likelihood of the presence of PCa (66).”
BackgroundInfluentialHerrmann, K., Bluemel, C., Weineisen, M., Schottelius, M., Wester, H., Czernin, J. G., Eberlein, U., Beykan, S., Lapa, C., Riedmiller, H. N., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.156133 · Cited by 148 · cited 1×
“PSMA-I&T (14) (68)Ga Imaging and therapy Reduced hepatic uptake compared with PSMA-11 (68)Ga-related disadvantages; lower lesion binding and higher background than for PSMA-11”
MethodChen, M., Zhang, Q. H., Zhang, C., Zhao, X., Marra, G., Gao, J., Lv, X., Zhang, B., Fu, Y. S., Wang, F., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.221010 · Cited by 124 · cited 1×
“Chen et al. (2019) used PSMA-PET and mpMRI alone or in a hybrid setting (PET/MRI) to improve the detection of clinically significant PCa in 54 men studied before radical prostatectomy, maintaining the final histopathology results as standard of reference 19 .”
MethodVaz, S. C., Hadaschik, B. A., Gabriel, M., Herrmann, K., Eiber, M., & Costa, D. C. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04529-8 · Cited by 121 · cited 1×
“We can conclude by saying that there are still many unanswered questions and that foremost among these is the question of the optimal time point between ADT administration and PSMA imaging to reduce or increase (depending on the clinical needs) the effect of ADT on PSMA expression (64).”
BackgroundCalais, J., Czernin, J. G., Fendler, W. P., Elashoff, D. A., & Nickols, N. G. (2019) · BMC Cancer · doi:10.1186/s12885-018-5200-1 · Cited by 120 · cited 8×
“Calais et al. enrolled 270 patients after prostatectomy and before SRT who underwent PSMA-PET at a PSA level < 1 ng/mL (median 0.48 ng/mL) 40 .”
MethodInfluentialBettermann, A. S., Zamboglou, C., Kiefer, S., Jilg, C. A., Spohn, S. K. B., Kranz-Rudolph, J., Fassbender, T. F., Bronsert, P., Nicolay, N. H., Gratzke, C., et al. (2019) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2019.07.005 · Cited by 118 · cited 1×
“The authors prospectively performed PSMA PET and mpMRI on 17 patients who were candidates for RP (21).”
BackgroundScheltema, M. J. V., Chang, J. I.-C., Stricker, P. D., van Leeuwen, P. J., Nguyen, Q. A., Ho, B., Delprado, W., Lee, J. W. J., Thompson, J. E., Cusick, T., et al. (2019) · British Journal of Urology · doi:10.1111/bju.14794 · Cited by 113 · cited 1×
“retrospectively enrolled 56 patients who underwent mpMRI and PSMA PET before RP (22).”
BackgroundRoberts, M. J., Morton, A., Donato, P., Kyle, S., Pattison, D. A., Thomas, P. A., Coughlin, G., Esler, R. C., Dunglison, N., Gardiner, R. A., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04944-2 · Cited by 101 · cited 1×
“Roberts et al. retrospectively enrolled 71 patients with MRI-guided, biopsy-proven PCa and PSMA-PET performed before surgery 23 .”
BackgroundGrubmüller, B., Rasul, S., Baltzer, P., Fajković, H., D’Andrea, D., Berndl, F., Maj‐Hes, A., Grubmüller, K. H., Mitterhauser, M., Wadsak, W., et al. (2019) · The Prostate · doi:10.1002/pros.23919 · Cited by 80
Ceci, F., Bianchi, L., Borghesi, M., Polverari, G., Farolfi, A., Briganti, A., Schiavina, R., Brunocilla, E., Castellucci, P., & Fanti, S. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04505-2 · Cited by 75 · cited 1×
“included 703 patients with PSA failure after RP, stratified according to different clinical settings, that is, first BCR, recurrence after salvage treatment, PSA persistence after radical surgery, and advanced stage of PCa before second-line systemic therapy (38).”
MethodSelf-citationSchmidt-Hegemann, N.-S., Fendler, W. P., Ilhan, H., Herlemann, A., Büchner, A., Stief, C. G., Eze, C., Rogowski, P., Li, M., Bartenstein, P., et al. (2018) · Radiation Oncology · doi:10.1186/s13014-018-0983-4 · Cited by 75
Ettala, O. O., Malaspina, S., Tuokkola, T., Luoto, P., Löyttyniemi, E., Boström, P. J., & Kemppainen, J. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04635-7 · Cited by 64 · cited 1×
“performance of PSMA PET in PCa patients at presentation, 9 treatment-naïve patients were enrolled (62).”
Ahmadzadehfar, H., Azgomi, K., Hauser, S., Wei, X. X., Yordanova, A., Gaertner, F. C., Kürpig, S., Strunk, H. M., & Essler, M. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.178533 · Cited by 59 · cited 1×
“In a retrospective analysis of 80 advanced-CRPC patients treated with (223)Ra-dichloride, the final outcome was significantly better in the group of patients studied with PSMA PET before treatment than in those who were staged only with conventional imaging (50).”
MethodBodar, Y. J. L., Jansen, B. H. E., van der Voorn, J. P., Zwezerijnen, G. J. C., Meijer, D., Nieuwenhuijzen, J. A., Boellaard, R., Hendrikse, N. H., Hoekstra, O. S., van Moorselaar, R. J. A., et al. (2020) · World Journal of Urology · doi:10.1007/s00345-020-03490-8 · Cited by 50
18F-Facbc in Prostate Cancer: A Systematic Review and Meta-Analysis
Laudicella, R., Albano, D., Alongi, P., Argiroffi, G., Bauckneht, M., Baldari, S., Bertagna, F., Boero, M., Vincentis, G. D., Sole, A. D., et al. (2019) · Cancers · doi:10.3390/cancers11091348 · Cited by 44 · cited 1×
“Choline, labelled either with 11 C or 18 F, and 18 F-fluciclovine are still broadly employed as metabolic PET tracers in clinical practice and their role for imaging biochemical recurrence and their impact on therapeutic management has been demonstrated in clinical trials 2–5 .”
MethodFarolfi, A., Gafita, A., Calais, J., Eiber, M., Afshar‐Oromieh, A., Spohn, F., Barbato, F., Weber, M., Ilhan, H., Cervati, V., et al. (2019) · The Journal of Urology · doi:10.1097/ju.0000000000000417 · Cited by 42
Self-citationSundahl, N., Gillessen, S., Sweeney, C. J., & Ost, P. (2020) · European Urology · doi:10.1016/j.eururo.2020.07.029 · Cited by 39 · cited 1×
“However, the type of imaging that best defines oligometastatic PCa for the purpose of MDT is debated 45 .”
BackgroundWondergem, M., van der Zant, F. M., Broos, W. A. M., Roeleveld, T. A., Donker, R., ten Oever, D., Geenen, R. W. F., & Knol, R. J. J. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04782-2 · Cited by 34
Farolfi, A., Hirmas, N., Gafita, A., Weber, M., Barbato, F., Wetter, A., Mei, R., Pianori, D., Hadaschik, B. A., Herrmann, K., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.246603 · Cited by 28
Self-citationTu, X., Zhang, C., Liu, Z., Shen, G., Wu, X., Nie, L., Chang, T., Xu, H., Bao, Y., Yang, L., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01365 · Cited by 26 · cited 1×
“In the most recently published meta-analysis the results of 11 studies, including 904 intermediate or high-risk patients, were grouped: pooled sensitivity and specificity on a patient basis were 63% (95% CI: 0.46–0.78) and 93% (95% CI: 0.88–0.96) 24 .”
InfluentialMeijer, D., Donswijk, M. L., Bodar, Y. J. L., van Leeuwen, P. J., van der Poel, H. G., Vogel, W. V., Nieuwenhuijzen, J. A., Hendrikse, N. H., Oprea‐Lager, D. E., & Vis, A. N. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.252528 · Cited by 21 · cited 1×
“In this setting of patients retrospective studies report a PSMA-PET positivity rate ranging from 67 to 70% 32–34 .”
Background
Cited by
Imaging-guided targeted radionuclide tumor therapy: From concept to clinical translation
Sun, J., Huangfu, Z., Yang, J., Wang, G., Hu, K., Gao, M., & Zhong, Z. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114538 · Cited by 57
The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer
Lin, C., Hadfield, M. J., Santopietro, A., Lagos, G., Cheng, L., El-Deiry, W. S., Aggarwal, R., Mega, A., Hyams, E., & Carneiro, B. A. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01131-0 · Cited by 20
Metadata
- Authors
- Farolfi, A., Calderoni, L., Mattana, F., Mei, R., Telo, S., Fanti, S., & Castellucci, P.
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2021-03-12
- Volume
- 62
- Issue
- 5
- Pages
- 596-604
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W3134860719
- Cited by
- 218
- References
- 59
- FWCI
- 19.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.